Effect of temporary IL-2 receptor MAB therapy on islet allograft in autoimmune diabetes.
Hahn
H J
HJ
Central Institute of Diabetes, Karlsburg, FRG.
Kuttler
B
B
Lucke
S
S
Dunger
A
A
Besch
W
W
Volk
H D
HD
Diamankstein
T
T
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology / Q000601:surgery*; D003921:Diabetes Mellitus, Experimental / Q000276:immunology / Q000601:surgery*; D005260:Female; D006084:Graft Rejection; D006943:Hyperglycemia / Q000276:immunology; D007515:Islets of Langerhans / Q000276:immunology; D016381:Islets of Langerhans Transplantation; D008297:Male; D051381:Rats; D011913:Rats, Inbred BB; D011917:Rats, Inbred Lew; D015375:Receptors, Interleukin-2 / Q000276:immunology*
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2